NCT07209189 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07209189
Title	Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) ((NeoScorch HN))
Acronym	NeoScorch HN
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications	nasal cavity carcinoma head and neck cancer sinonasal undifferentiated carcinoma head and neck squamous cell carcinoma olfactory neuroblastoma
Therapies	Toripalimab-tpzi Cisplatin + Docetaxel + Toripalimab-tpzi Carboplatin + Docetaxel + Toripalimab-tpzi
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST